Fig. 6

Effects of sevoflurane on RhoA/pMLC/F-actin pathway in mouse lung epithelial (MLE-12) cells, treated or not with RAGE antagonist peptide (RAP). a total myosin light chain (MLC) and phosphorylated myosin light chain 2 (Ser19) (pMLC2) levels at 6 h in untreated MLE-12 cells (Medium) and cells exposed to sevoflurane alone (Sevo), cytomix alone (Cyto), cytomix and sevoflurane (Cyto + Sevo), cytomix and RAP (Cyto + RAP) or with cytomix, RAP, and sevoflurane (Cyto + RAP + Sevo). b Protein expression levels were quantified and standardized by GAPDH protein level, and pMLC levels were standardized by total MLC levels, expressed as ratios to those in the Medium group, and reported as medians with interquartile ranges. c Immunostaining after 6 h of treatment of pMLC and F-actin was performed in identical conditions. Cells were fixed, permeabilized, and stained with antibodies, followed by A488 secondary antibodies and Hoechst. All images were acquired by fluorescent microscope with a 40× objective. Scale bar: 50 μm. d RhoA activity was standardized by total RhoA protein level at 30 min in identical conditions. All quantitative results are reported as medians with interquartile ranges. One-way ANOVA was performed, with post-hoc comparisons if ANOVA results showed significance (compared to the Medium group: *p < 0.05; **p < 0.01; compared to the Cyto group: ^#p < 0.05; ^##p < 0.01)